{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T08:28:37Z","timestamp":1771921717803,"version":"3.50.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although dose reduction is the guideline-recommended tapering strategy for roxadustat to maintain target hemoglobin levels in peritoneal dialysis (PD) patients during the maintenance phase, reducing the administration frequency represents another potential clinical approach. However, the specific efficacy of this strategy in sustaining target hemoglobin levels remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective cohort study conducted from 1 January 2021 to 31 December 2024, enrolling PD patients from three dialysis centers in South China. Participants who achieved target hemoglobin levels were stratified into two groups based on roxadustat tapering strategies: The dose-reduction group, in which the per-dose amount was gradually decreased while maintaining the administration frequency, and the frequency-reduction group, in which the administration frequency was reduced without changing the per-dose amount. During a 12-month follow-up period, with assessments conducted every 3\u202fmonths, mean hemoglobin levels, hemoglobin target attainment rates, and hemoglobin variability\u2014evaluated using the residual standard deviation (RSD) method\u2014were compared between the two tapering strategies. The association between hemoglobin target non-attainment and tapering strategies was analyzed using Cox proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 402 PD patients included in the analysis, the mean age was 45.3\u202f\u00b1\u202f13.8\u202fyears and 55.5% were male. No significant difference was observed in the hemoglobin change trend and mean hemoglobin levels between the two groups throughout the follow-up period. Compared to the dose-reduction group, the patients who reduced dosing frequency demonstrated significantly higher hemoglobin target attainment rates at months 3 (64.1% vs. 40.4%), 6 (55.6% vs. 43.2%), and 12 (49.2% vs. 36.6%; all\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.05). In addition, the patients in this group exhibited a lower mean Res-SD value (12.3 vs. 15.5;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.05). Moreover, the frequency-reduction strategy was associated with a significantly lower risk of hemoglobin target non-attainment (adjusted hazards ratio [HR] 0.64, 95% CI 0.50\u20130.82;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Compared to the dose-reduction group, the frequency-reduction group showed higher hemoglobin target attainment rates, lower hemoglobin variability, and a reduced risk of hemoglobin target non-attainment. The frequency-reduction strategy appears to be a potential tapering approach for peritoneal dialysis (PD) patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1708916","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:39:39Z","timestamp":1768372779000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Frequency-reduction strategy of roxadustat in patients undergoing peritoneal dialysis: a multi-center retrospective cohort study"],"prefix":"10.3389","volume":"12","author":[{"given":"Xi","family":"Mi","sequence":"first","affiliation":[{"name":"Division of Nephrology, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]},{"name":"National Clinical Research Center for Kidney Disease","place":["Guangzhou, China"]},{"name":"State Key Laboratory of Organ Failure Research","place":["Guangzhou, China"]},{"name":"Guangdong Provincial Institute of Nephrology","place":["Guangzhou, China"]},{"name":"Guangdong Provincial Key Laboratory of Renal Failure Research","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanying","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]},{"name":"National Clinical Research Center for Kidney Disease","place":["Guangzhou, China"]},{"name":"State Key Laboratory of Organ Failure Research","place":["Guangzhou, China"]},{"name":"Guangdong Provincial Institute of Nephrology","place":["Guangzhou, China"]},{"name":"Guangdong Provincial Key Laboratory of Renal Failure Research","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijing","family":"Fang","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]},{"name":"National Clinical Research Center for Kidney Disease","place":["Guangzhou, China"]},{"name":"State Key Laboratory of Organ Failure Research","place":["Guangzhou, China"]},{"name":"Guangdong Provincial Institute of Nephrology","place":["Guangzhou, China"]},{"name":"Guangdong Provincial Key Laboratory of Renal Failure Research","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics and Traumatology, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhong","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]},{"name":"National Clinical Research Center for Kidney Disease","place":["Guangzhou, China"]},{"name":"State Key Laboratory of Organ Failure Research","place":["Guangzhou, China"]},{"name":"Guangdong Provincial Institute of Nephrology","place":["Guangzhou, China"]},{"name":"Guangdong Provincial Key Laboratory of Renal Failure Research","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]},{"name":"National Clinical Research Center for Kidney Disease","place":["Guangzhou, China"]},{"name":"State Key Laboratory of Organ Failure Research","place":["Guangzhou, China"]},{"name":"Guangdong Provincial Institute of Nephrology","place":["Guangzhou, China"]},{"name":"Guangdong Provincial Key Laboratory of Renal Failure Research","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Zhong","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]},{"name":"National Clinical Research Center for Kidney Disease","place":["Guangzhou, China"]},{"name":"State Key Laboratory of Organ Failure Research","place":["Guangzhou, China"]},{"name":"Guangdong Provincial Institute of Nephrology","place":["Guangzhou, China"]},{"name":"Guangdong Provincial Key Laboratory of Renal Failure Research","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Dongguan Tungwah Hospital","place":["Dongguan, China"]},{"name":"Dongguan Key Laboratory of Precise Prevention & Treatment of Chronic Kidney Disease and Complications","place":["Dongguan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianrui","family":"Dou","sequence":"additional","affiliation":[{"name":"The Eighth Affiliated Hospital, Southern Medical University (The First People\u2019s Hospital of Shunde)","place":["Foshan, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Ai","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Nanfang Hospital, Southern Medical University","place":["Guangzhou, China"]},{"name":"National Clinical Research Center for Kidney Disease","place":["Guangzhou, China"]},{"name":"State Key Laboratory of Organ Failure Research","place":["Guangzhou, China"]},{"name":"Guangdong Provincial Institute of Nephrology","place":["Guangzhou, China"]},{"name":"Guangdong Provincial Key Laboratory of Renal Failure Research","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/1744-9987.14177","article-title":"Current therapeutic approach of chronic kidney disease-mineral and bone disorder","volume":"28","author":"Zaimi","year":"2024","journal-title":"Ther Apher Dial"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"642296","DOI":"10.3389\/fmed.2021.642296","article-title":"Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents","volume":"8","author":"Portoles","year":"2021","journal-title":"Front Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/ckj\/sfaa054","article-title":"Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis","volume":"13","author":"Evans","year":"2020","journal-title":"Clin Kidney J"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12882-020-01746-4","article-title":"Impact of chronic kidney disease and anemia on health-related quality of life and work productivity: analysis of multinational real-world data","volume":"21","author":"van Haalen","year":"2020","journal-title":"BMC Nephrol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1053\/j.jrn.2019.11.003","article-title":"Associations of hemoglobin levels with health-related quality of life, physical activity, and clinical outcomes in persons with stage 3-5 nondialysis ckd","volume":"30","author":"Hoshino","year":"2020","journal-title":"J Ren Nutr"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/1744-9987.12712","article-title":"Burden of anemia in chronic kidney disease patients in Japan: a literature review","volume":"22","author":"Akizawa","year":"2018","journal-title":"Ther Apher Dial"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3265\/Nefrologia.pre2013.Dec.12261","article-title":"Prevalence of anaemia and its clinical management in patients with stages 3-5 chronic kidney disease not on dialysis in Catalonia: micenas i study","volume":"34","author":"Cases-Amenos","year":"2014","journal-title":"Nefrologia"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"8065691","DOI":"10.1155\/2018\/8065691","article-title":"Factors influencing hemoglobin variability and its association with mortality in hemodialysis patients","volume":"2018","author":"Bal","year":"2018","journal-title":"ScientificWorldJournal"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/ki.2014.114","article-title":"Association between hemoglobin variability, serum ferritin levels, and adverse events\/mortality in maintenance hemodialysis patients","volume":"86","author":"Kuragano","year":"2014","journal-title":"Kidney Int"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1038\/s41598-023-28029-w","article-title":"Association of hemoglobin variability with the risk of cardiovascular disease: a nationally representative retrospective cohort study from South Korea","volume":"13","author":"Lee","year":"2023","journal-title":"Sci Rep"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e1223","DOI":"10.34067\/KID.0000000000000204","article-title":"Anemia treatment, hemoglobin variability, and clinical events in patients with nondialysis-dependent ckd in Japan","volume":"4","author":"Kuragano","year":"2023","journal-title":"Kidney360"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/nep.13835","article-title":"Recommendations by the Asian Pacific Society of Nephrology (APSN) on the appropriate use of HIF-PH inhibitors","volume":"26","author":"Yap","year":"2021","journal-title":"Nephrology (Carlton)"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1681\/ASN.2020081150","article-title":"Roxadustat for treating anemia in patients with ckd not on dialysis: results from a randomized phase 3 study","volume":"32","author":"Fishbane","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.26355\/eurrev_202401_34917","article-title":"Hemoglobin variability in patients receiving epo and roxadustat during maintenance hemodialysis: a self-control study","volume":"28","author":"Wang","year":"2024","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1159\/000508100","article-title":"A phase 3, multicenter, randomized, two-arm, open-label study of intermittent oral dosing of roxadustat for the treatment of anemia in japanese erythropoiesis-stimulating agent-naive chronic kidney disease patients not on dialysis","volume":"144","author":"Akizawa","year":"2020","journal-title":"Nephron Clin Pract"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"Roxadustat (fg-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study","volume":"67","author":"Provenzano","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1681\/ASN.2020111638","article-title":"Roxadustat versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: results from the randomized phase 3 rockies study","volume":"33","author":"Fishbane","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1093\/ndt\/gfv302","article-title":"Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (fg-4592) to treat anemia in nondialysis-dependent chronic kidney disease (ndd-ckd) patients","volume":"30","author":"Besarab","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"982","DOI":"10.2215\/CJN.06890615","article-title":"Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (fg-4592) for the treatment of anemia in patients with ckd","volume":"11","author":"Provenzano","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat treatment for anemia in patients undergoing long-term dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/s0272-6386(97)70028-3","article-title":"Nkf-doqi clinical practice guidelines for peritoneal dialysis adequacy","volume":"30","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.2215\/CJN.02390508","article-title":"Association of hemoglobin variability and mortality among contemporary incident hemodialysis patients","volume":"3","author":"Brunelli","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1007\/s12325-023-02741-5","article-title":"Roxadustat and oral iron absorption in chinese patients with anemia of chronic kidney disease: a randomized, open-label, phase 4 study (Altai)","volume":"41","author":"Wu","year":"2024","journal-title":"Adv Ther"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/1744-9987.13609","article-title":"Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients","volume":"25","author":"Akizawa","year":"2021","journal-title":"Ther Apher Dial"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3904\/kjim.2023.520","article-title":"A retrospective study on the efficacy of roxadustat in peritoneal dialysis patients with erythropoietin hyporesponsiveness","volume":"39","author":"Liu","year":"2024","journal-title":"Korean J Intern Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s40262-021-01095-x","article-title":"Clinical pharmacokinetics and pharmacodynamics of roxadustat","volume":"61","author":"Czock","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1007\/s12325-019-00943-4","article-title":"Roxadustat treatment of chronic kidney disease-associated anemia in japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial","volume":"36","author":"Akizawa","year":"2019","journal-title":"Adv Ther"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.ekir.2021.12.025","article-title":"Randomized study on the efficacy of standard versus low roxadustat dose for anemia in patients on peritoneal dialysis","volume":"7","author":"Yang","year":"2022","journal-title":"Kidney Int Rep"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.ekir.2025.01.027","article-title":"Randomized trial of lower-dose roxadustat efficacy and safety in non-dialysis-dependent ckd-associated anemia","volume":"10","author":"Li","year":"2025","journal-title":"Kidney Int Rep"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1708916\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T06:54:12Z","timestamp":1771916052000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1708916\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":30,"alternative-id":["10.3389\/fmed.2025.1708916"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1708916","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"article-number":"1708916"}}